Back to top

cell-therapy: Archive

Zacks Equity Research

CRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss Estimates

CRSP posts a wider Q1 loss and revenues miss, pressuring shares, even as Casgevy sales grow and cash reserves strengthen from recent financing.

VRTXNegative Net Change CPRXNegative Net Change CRSPNegative Net Change CSTLNegative Net Change